Literature DB >> 31655418

Preparation of gentiobiose-derived oligosaccharides by glucansucrase E81 and determination of prebiotic and immune-modulatory functions.

Hümeyra İspirli1, Ian J Colquhoun2, Engin Şahin3, Osman Sagdic1, Enes Dertli4.   

Abstract

Gentiobiose-derived oligosaccharides were synthesized by the acceptor reaction of glucansucrase E81 obtained from Lactobacillus reuteri E81 with sucrose and gentiobiose as donor-acceptor sugars, respectively. The reaction products were monitored by TLC analysis and gentiobiose-derived oligosaccharides up to DP 8 were formed during the acceptor reaction as determined by ESI-MS/MS analysis. The glycosylation of the gentiobiose with α-(1 → 6) linkages and α-(1 → 3) linkages was shown by 1H and 13C NMR analysis confirming the structure of these gentiobiose-derived oligosaccharides. The in vitro prebiotic function of the oligosaccharides was determined in which probiotic strains were stimulated whereas no growth was observed in pathogen strains. Gentiobiose-derived oligosaccharides showed immune-modulatory functions in vitro and triggered the production of IL-4, IL12 and TNF-α cytokines in HT29 cells in a dose dependent manner. This study showed the production and functional characterisation of gentiobiose-derived oligosaccharides establishing a promising avenue for future applications.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Gentiobiose-derived oligosaccharides; Glucansucrase; Immune modulation; Prebiotic

Mesh:

Substances:

Year:  2019        PMID: 31655418     DOI: 10.1016/j.carres.2019.107837

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  1 in total

1.  Transcriptomic and Metabolomic Analyses Provide Insights into the Growth and Development Advantages of Triploid Apostichopus japonicus.

Authors:  Jiahui Xie; Yi Sun; Yue Cao; Lingshu Han; Yuanxin Li; Beichen Ding; Chuang Gao; Pengfei Hao; Xin Jin; Yaqing Chang; Jian Song; Donghong Yin; Jun Ding
Journal:  Mar Biotechnol (NY)       Date:  2022-02-05       Impact factor: 3.619

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.